Literature DB >> 3680508

Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics.

H C Porchet1, N L Benowitz, L B Sheiner, J R Copeland.   

Abstract

Persons exposed to nicotine develop tolerance to many of its effects. When heart rate and forearm venous blood concentration are plotted against time after intravenous administration of nicotine, a greater increase in heart rate is seen for a given nicotine concentration during the rising phase of nicotine concentrations than during the decreasing phase. This could be due to acute tolerance or to more rapid distribution of drug to effect site (brain) than to venous blood. To distinguish between these possibilities, six rabbits were given nicotine intravenously. Blood samples were taken from the internal jugular vein (reflecting brain concentration), and the femoral vein and artery. Brain concentrations peaked before femoral venous concentrations. Seven men received intravenous infusions of nicotine. Peripheral venous blood concentrations and cardiovascular responses were measured. Heart rate peaked before venous concentrations. A physiological kinetic model, fit to the rabbit data, was scaled to humans and used to predict "brain" concentrations in them. Heart rate and predicted brain concentrations peaked simultaneously. We conclude that the rapid development of tolerance to the cardioaccelerating effect of nicotine can be attributed, at least in part, to its distribution kinetics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680508      PMCID: PMC442405          DOI: 10.1172/JCI113227

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Positional nystagmus in man during and after alcohol intoxication.

Authors:  G ASCHAN; M BERGSTEDT; L GOLDBERG; L LAURELL
Journal:  Q J Stud Alcohol       Date:  1956-09

2.  Lipid solubility and drug penetration of the blood brain barrier.

Authors:  W H Oldendorf
Journal:  Proc Soc Exp Biol Med       Date:  1974-12

3.  Influence of tobacco abstinence on the disposition kinetics and effects of nicotine.

Authors:  B L Lee; N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

Review 4.  Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase.

Authors:  T K Harden
Journal:  Pharmacol Rev       Date:  1983-03       Impact factor: 25.468

5.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

6.  Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids.

Authors:  P Jacob; M Wilson; N L Benowitz
Journal:  J Chromatogr       Date:  1981-01-02

7.  Tolerance to organic nitrates: clinical and experimental perspectives.

Authors:  P W Armstrong; J A Moffat
Journal:  Am J Med       Date:  1983-06-27       Impact factor: 4.965

8.  Disposition kinetics and effects of intravenous nicotine.

Authors:  J Rosenberg; N L Benowitz; P Jacob; K M Wilson
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

Review 9.  Nitrate tolerance.

Authors:  C V Leier
Journal:  Am Heart J       Date:  1985-07       Impact factor: 4.749

10.  Kinetics of cocaine distribution, elimination, and chronotropic effects.

Authors:  M J Chow; J J Ambre; T I Ruo; A J Atkinson; D J Bowsher; M W Fischman
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

View more
  19 in total

1.  Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation.

Authors:  Franziska Schaedeli; Maria Pitsiu; Neal L Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

2.  Modeling nicotine arterial-venous differences to predict arterial concentrations and input based on venous measurements: application to smokeless tobacco and nicotine gum.

Authors:  Maria Pitsiu; Jean-Michel Gries; Neal Benowitz; Steven G Gourlay; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

3.  Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences.

Authors:  Stina Syvänen; Gunnar Blomquist; Lieuwe Appel; Margareta Hammarlund-Udenaes; Bengt Långström; Mats Bergström
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

5.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

6.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

7.  Clockwise hysteresis or proteresis.

Authors:  P Girard; J P Boissel
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

8.  The use of multiple doses and pharmacodynamic system analysis to distinguish between dispositional delays and time-variant pharmacodynamics.

Authors:  M R Gastonguay; S L Schwartz
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

Review 9.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

10.  The role of vasopressin in the nicotine-induced stimulation of ACTH and cortisol in men.

Authors:  J Stalke; O Hader; V Bähr; J Hensen; G Scherer; W Oelkers
Journal:  Clin Investig       Date:  1992 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.